Prediction Analysis News Today

Multigene assays allow for patients to receive personalized breast cancer treatment by identifying promising therapeutic targets, which could improve patient clinical outcomes in the long term and help providers better understand tumor biology.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.